ISSN: 1300-7777 E-ISSN: 1308-5263
Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study [Turk J Hematol]
Turk J Hematol. 2018; 35(3): 181-184 | DOI: 10.4274/tjh.2017.0437  

Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study

Kenji Matsumoto1, Shin Fujisawa2, Taiki Ando2, Megumi Koyama3, Satoshi Koyama4, Yoshimi Ishii2, Ayumi Numata3, Wataru Yamamoto3, Kenji Motohashi2, Maki Hagihara1, Hideaki Nakajima1
1Yokohama City University Faculty of Medicine, Department of Hematology and Clinical Immunology, Yokohama, Japan
2Yokohama City University Faculty of Medicine, Department of Hematology, Yokohama, Japan
3Kanagawa Cancer Center, Clinic of Medical Oncology, Yokohama, Japan
4Kanagawa Cancer Center, Clinic of Hematology, Yokohama, Japan

Objective: Useful prognostic biomarkers for diffuse large B-cell lymphoma (DLBCL) patients have been reported. To determine the prognostic value of hemoglobin (Hb) level in DLBCL patients, we performed a retrospective study.
Materials and Methods: We evaluated disease outcome, progressionfree survival (PFS), overall survival as the endpoint, and clinical and laboratory factors affecting the outcome of 185 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy during 2004-2014.
Results: The study group included 121 men and 64 women with a median age of 66 years minimum-maximum: 21-83 years. In univariate analysis, factors independently associated with worse PFS were Eastern Cooperative Oncology Group performance status ≥2, Ann Arbor stage III or IV, anemia with Hb levels of <10 g/dL, and serum albumin of <3.5 g/ dL. In multivariate analysis, anemia with Hb levels of <10 g/dL and Ann Arbor stage III or IV were found to be international index-independent prognostic factors (hazard ratio: 2.4; p=0.04).
Conclusion: Anemia is an independent prognostic marker of poor outcome in DLBCL patients. Hb can be an easily available prognostic marker for risk stratification in these patients.

Keywords: Anemia, Diffuse large B-cell lymphoma, Hemoglobin


Anemi Diffüz büyük B-hücreli lenfoma Hastalarında Kötü Prognozla İlişkilidir: Tek Merkezli Retrospektif Bir Çalışma

Kenji Matsumoto1, Shin Fujisawa2, Taiki Ando2, Megumi Koyama3, Satoshi Koyama4, Yoshimi Ishii2, Ayumi Numata3, Wataru Yamamoto3, Kenji Motohashi2, Maki Hagihara1, Hideaki Nakajima1
1Yokohama City University Faculty of Medicine, Department of Hematology and Clinical Immunology, Yokohama, Japan
2Yokohama City University Faculty of Medicine, Department of Hematology, Yokohama, Japan
3Kanagawa Cancer Center, Clinic of Medical Oncology, Yokohama, Japan
4Kanagawa Cancer Center, Clinic of Hematology, Yokohama, Japan

Amaç: Diffüz büyük B hücreli lenfoma (DBBHL) hastaları için yararlı prognostik belirteçler bildirilmiştir. DBBHL hastalarında hemoglobin (Hb) düzeyleri ile prognoz ilişkisini araştırmak amacıyla retrospektif bir çalışma yaptık.
Gereç ve Yöntem: 2004-2014 yılları arasında rituksimab, siklofosfamid, doksorubisin, vinkristin ve prednizolon tedavisi almış olan 185 DBBHL hastasının klinik ve laboratuvar bulguları değerlendirildi ve bunların hastalık sonuçlarına, ilerlemesiz sağkalım (PFS) ve toplam sağkalıma (TS) etkileri araştırıldı.
Bulgular: Araştırma grubunda 121 erkek ve 64 kadın vardı, ortanca yaş 66 yıldı (minimum-maksimum: 21-83 yıl). Tek değişkenli analizde Eastern Cooperative Oncology Group performans durumunun ≥2 olması, Ann Arbor evre III veya IV olması ve Hb değerinin <10 g/dL ile anemi olması PFS ve TS’yi etkileyen bağımsız değişkenler olarak bulundu. Çok değişkenli analizde ise Hb değerinin <10 g/dL ile anemi ve Ann Arbor evre III veya IV olması uluslararası indeks-bağımsız prognostik faktörler olarak bulundu (Hazard ratio: 2,4; p=0,04).
Sonuç: Anemi, DLBCL hastalarında kötü sonuçların bağımsız prognostik bir göstergesidir. Hb, bu hastalarda risk sınıflandırması için kolayca bulunabilen bir prognostik belirteç olabilir.

Anahtar Kelimeler: Anemi, Diffüz büyük B-hücreli lenfoma, Hemoglobin


Kenji Matsumoto, Shin Fujisawa, Taiki Ando, Megumi Koyama, Satoshi Koyama, Yoshimi Ishii, Ayumi Numata, Wataru Yamamoto, Kenji Motohashi, Maki Hagihara, Hideaki Nakajima. Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study. Turk J Hematol. 2018; 35(3): 181-184

Corresponding Author: Kenji Matsumoto, Japan


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2017) = 0.650